Drug
Galcanezumab
Galcanezumab: highest development phase Phase 2, developed by Eli Lilly. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| Galcanezumab NCT02959177 | Phase 2 | Migraine |
Latest
No recent events.
Follow Galcanezumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.